+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Human Growth Hormones Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2023

  • ID: 4771573
  • Report
  • Region: Global
  • Azoth Analytics
UP TO OFF
until Jul 31st 2019
1 of 4

FEATURED COMPANIES

  • Ascendis Pharma A/S
  • Novo Nordisk A/S
  • Opko Health Inc.
  • Pfizer Inc.
  • Versartis Inc.
  • MORE
The report presents the market potential of four major pipeline drugs (TransCon-hGH, Somapacitan, Somavaratan, Somatrogonmeant) for the treatment of human Growth Hormone Deficiency (GHD). These four drugs that fall in the various categories of paediatrics and adults by end user have been recognized as being clinically effective in human Growth Hormone Deficiency treatment. Expected to be launched in the market within the next 4-5 years, these four potential drugs are likely to bring about major changes in the way Growth Hormone Deficiency is treated globally.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market by assessing the potential of the four drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the four drugs, the product profile, description and regulatory phase of each of the four drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the four drugs to present the current perspective.

The report titled “Global Human Growth Hormones Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential -Forecast to 2023” also analyzes the overall sizing, growth and forecast of Growth Hormone Deficiency Drugs Market for the global market.

Over the recent years, the human Growth Hormone Deficiency Drugs market is growing rapidly due to rising prevalence of patients with Growth Hormone Deficiency (GHD) around the world. Globally, the growth of human Growth Hormone Deficiency Drugs market is driven by increased penetration of drugs by market players coupled with introduction of new drugs with improved patient compliance.

The global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market is projected to display a robust growth during 2018 -2023, chiefly driven by low efficacy and poor dosing schedules of present drugs and improved safety and efficacy of investigational drugs. The report has covered and analysed the present human Growth Hormone Deficiency (GHD) drugs in the market and has also analysed potential of four major pipeline drugs. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation.

Scope of the Report

Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Assessment -TransCon-hGH, Somapacitan, Somavaratan, Somatrogon (Forecast Period: 2020-2023)
  • Market Potential
  • Clinical Trials
  • Product Description
  • Regulatory Phases
  • 7Ps Analysis
Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market -Sizing and Growth
  • Actual Period: 2013-2017
  • Forecast Period: 2018-2023
Regional Analysis - Human Growth Hormone Deficiency (GHD) Pipeline Drugs Market -Sizing and Growth: North America, Europe, Rest of the World
  • Actual Period: 2013-2017
  • Forecast Period: 2018-2023
Country Analysis - Human Growth Hormone Deficiency (GHD) Pipeline Drugs Market -Sizing and Growth: US, UK, France, Spain, Germany, Japan
  • Actual Period: 2013-2017
  • Forecast Period: 2018-2023
Other Report Highlights
  • Company Analysis -Ascendis Pharma A/S, Novo Nordisk A/S, Versartis Inc., Opko Health Inc., Pfizer Inc.
Customization of the Report

The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Ascendis Pharma A/S
  • Novo Nordisk A/S
  • Opko Health Inc.
  • Pfizer Inc.
  • Versartis Inc.
  • MORE
1. Research Methodology

2. Executive Summary

3. Growth Hormone Deficiency Drugs Product - An Overview
3.1. Growth Hormone (GH) and its Function
3.2. Growth Hormone Deficiency (GHD) and its Symptoms
3.3. Causes of Growth Hormone Deficiency (GHD)

4. Diagnosis of Growth Hormone Deficiency (GHD)

5. Treatment of Growth Hormone Deficiency (GHD)

6. Global Growth Hormone Drugs Market
6.1. Global Growth Hormone Drugs Market Size, By value, 2013-2017
6.2. Global Growth Hormone Drugs Market Size, By value, 2018-2023

7. Global Growth Hormone Deficiency Drugs Market
7.1. Global Growth Hormone Deficiency Drugs Market Size, By value, 2013-2017
7.2. Global Growth Hormone Deficiency Drugs Market Size, By value, 2018-2023

8. Global Growth Hormone Deficiency Drugs Market, By End User
8.1. Global Growth Hormone Deficiency Drugs Market, By End User: Break down (%)
8.1.1. Global Growth Hormone Deficiency Drugs Market, By End User: 2017%
8.1.2. Global Growth Hormone Deficiency Drugs Market, By End User: 2023%
8.2. Global Growth Hormone Deficiency Drugs Market, By End User – By Pediatrics
8.2.1. By Value (2013 – 2017)
8.2.2. By Value (2018 – 2023)
8.3. Global Growth Hormone Deficiency Drugs Market, By End User – By Adult
8.3.1. By Value (2013 – 2017)
8.3.2. By Value (2018 – 2023)

9. Global Growth Hormone Deficiency Drugs Market: Regional Analysis
9.1. North America Growth Hormone Deficiency Drugs Market
9.1.1. By Value (2013 – 2017)
9.1.2. By Value (2018 – 2023)
9.2. Europe Growth Hormone Deficiency Drugs Market
9.2.1. By Value (2013 – 2017)
9.2.2. By Value (2018 – 2023)
9.3. ROW Growth Hormone Deficiency Drugs Market
9.3.1. By Value (2013 – 2017)
9.3.2. By Value (2018 – 2023)

10. Global Growth Hormone Deficiency Drugs Market: Country Analysis
10.1. U.S. Growth Hormone Deficiency Drugs Market
10.1.1. By Value (2013 – 2017)
10.1.2. By Value (2018 – 2023)
10.2. U.K. Growth Hormone Deficiency Drugs Market
10.2.1. By Value (2013 – 2017)
10.2.2. By Value (2018 – 2023)
10.3. France Growth Hormone Deficiency Drugs Market
10.3.1. By Value (2013 – 2017)
10.3.2. By Value (2018 – 2023)
10.4. Germany Growth Hormone Deficiency Drugs Market
10.4.1. By Value (2013 – 2017)
10.4.2. By Value (2018 – 2023)
10.5. Spain Growth Hormone Deficiency Drugs Market
10.5.1. By Value (2013 – 2017)
10.5.2. By Value (2018 – 2023)
10.6. Japan Growth Hormone Deficiency Drugs Market
10.6.1. By Value (2013 – 2017)
10.6.2. By Value (2018 – 2023)

11. human Growth Hormone Deficiency (hGHD) Pipeline Drugs Coverage
11.1. hGHD Pipeline Drugs – TransCon-hGH
11.1.1. Description
11.1.2. Regulatory Milestones
11.1.3. Advantages & Disadvantages
11.1.4. Product Profile & Launch Date
11.1.5. Clinical Trials and Status
11.1.6. Pivotal Clinical Trials and Results
11.1.7. TransCon-hGH – Global Market Potential
11.1.8. TransCon-hGH – Global Market Potential
11.2. hGHD Pipeline Drugs – Somapacitan
11.2.1. Description
11.2.2. Regulatory Milestones
11.2.3. Advantages & Disadvantages
11.2.4. Product Profile & Launch Date
11.2.5. Clinical Trials and Status
11.2.6. Pivotal Clinical Trials and Results
11.2.7. Somapacitan – Global Market Potential
11.2.8. Somapacitan – 7Ps Analysis
11.3. hGHD Pipeline Drugs – Somavaratan
11.3.1. Description
11.3.2. Regulatory Milestones
11.3.3. Advantages & Disadvantages
11.3.4. Product Profile & Launch Date
11.3.5. Clinical Trials and Status
11.3.6. Pivotal Clinical Trials and Results
11.3.7. Somavaratan – Global Market Potential
11.3.8. Somavaratan – 7Ps Analysis
11.4. hGHD Pipeline Drugs – Somatrogon/ Lagova
11.4.1. Description
11.4.2. Regulatory Milestones
11.4.3. Advantages & Disadvantages
11.4.4. Product Profile & Launch Date
11.4.5. Clinical Trials and Status
11.4.6. Pivotal Clinical Trials and Results
11.4.7. Somatrogon/ Lagova – Global Market Potential
11.4.8. Somatrogon/ Lagova – 7Ps Analysis
11.5. Competitive Landscape

12. Company Profiles
12.1. Ascendis Pharma A/S
12.2. Novo Nordisk A/S
12.3. Versartis Inc.
12.4. Opko Health, Inc.
12.5. Pfizer Inc
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Ascendis Pharma A/S
  • Novo Nordisk A/S
  • Versartis Inc.
  • Opko Health Inc.
  • Pfizer Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4771573
Adroll
adroll